Comparative Effects of 2 Diets in Veterans With the Metabolic Syndrome

NCT ID: NCT00852475

Last Updated: 2017-02-02

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-02-28

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to examine the effects of 2 commonly used diets, a Mediterranean monounsaturated fatty acid enriched (MUFA) or AHA polyunsaturated (PUFA) enriched diet combined with the VA Managing Overweight/Obesity for Veterans Everywhere (MOVE!) program so as to determine which one is superior in reducing cardiometabolic risk factors associated with Metabolic Syndrome. The risk factors considered include lipids and lipoproteins, inflammatory markers such as CRP and adiponectin, endothelium-dependent flow-mediated vasodilatation (FMD) and the postprandial lipid responses to a meal.

Cardiometabolic risk factors will be determined by measuring several cardiovascular risk associated parameters including:

Biochemical measurements of lipids and inflammatory markers, body composition and VO2max (Specific Objective 1, Descriptive).

Postprandial response to a meal challenge and endothelial vasoreactivity (FMD) assessed by BART (Specific Objective 2, Physiological).

Determination of the effects on postheparin lipases and transfer protein activity, visceral adipose tissue (VAT) and homeostasis model assessment-estimated insulin resistance (HOMA-IR) (Specific Objective 3, Mechanistic)

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The Metabolic Syndrome (MetS) is a common problem among Veterans and is associated with a greater likelihood of cardiovascular disease (CVD). The Mediterranean diet is the only popular diet that has been shown to reduce CVD event rates but the extent to which monounsaturated fatty acid (MUFA) or polyunsaturated fatty acid (PUFA) enrichment results in improvement in parameters of MetS is unresolved. Similarly, while low intensity exercise improves the CVD risk factor profile, there have been no comparative investigations comparing MUFA and PUFA enriched diets and exercise in patients with MetS that have extended beyond 1 year. Recently, the VA established the MOVE! program, a national weight management program designed to help Veterans lose weight. Using the VA promoted program, we will perform a systematic evaluation of the effects of dietary fat composition \[comparison between MUFA-enriched and PUFA enriched diet\] with MOVE!. We hypothesize that a MUFA-enriched diet consisting of antioxidant, lipid reducing and insulin sensitizing properties will be superior to the less palatable PUFA-enriched diet on improving cardiometabolic parameters associated with MetS. Specifically, the MUFA MOVE! program is expected to lead to greater improvements than the PUFA MOVE! program in body composition and aerobic fitness (Specific Aim 1), endothelial dependent flow mediated vasodilatation and the postprandial lipid response to a meal load (Specific Aim 2) and the mechanisms (lipolytic and lipid transfer protein activity, homeostasis model assessment-estimated insulin resistance) responsible for these effects (Specific Aim 3). Collectively, these studies will advance our understanding of mechanisms underlying the differential effects of MUFA and PUFA-enriched dietary regimens on cardiometabolic health and when combined with the MOVE! program, will provide new and useful information to Veterans (and the general public) interested in optimizing their diets for CVD disease prevention and improved vascular health.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MUFA

Assignment to monounsaturated enriched diet with exercise. This represents the MUFA MOVE! program

Group Type PLACEBO_COMPARATOR

MUFA MOVE! (Monounsaturated fatty enriched diet)

Intervention Type DIETARY_SUPPLEMENT

MUFA MOVE!diet and exercise program

PUFA

Assignment to polyunsaturated enriched diet with exercise. This represents the PUFA MOVE! program

Group Type ACTIVE_COMPARATOR

PUFA MOVE! (Polyunsaturated fatty acid enriched diet)

Intervention Type DIETARY_SUPPLEMENT

PUFA MOVE! diet and exercise program

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MUFA MOVE! (Monounsaturated fatty enriched diet)

MUFA MOVE!diet and exercise program

Intervention Type DIETARY_SUPPLEMENT

PUFA MOVE! (Polyunsaturated fatty acid enriched diet)

PUFA MOVE! diet and exercise program

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Presence of 3 or more of the following):

* Waist circumference \>102 cm in men or \>88 cm women
* Treated Hypertension or Untreated Blood pressure \>130/85 and \< 160/100 mm Hg
* Treated Hyperglycemia or Untreated Fasting blood glucose (FBG) \>100 mg/dL (based on 2006 guidelines)
* Treated Hyperlipidemia or Untreated Triglycerides \> 150 mg/dL
* HDL-C \< 40 mg/dL men \< 50 mg/dL women

Exclusion Criteria

* Decompensated heart failure (NYHA Class IV);
* Severe Pulmonary disease (Unable to walk on a treadmill at 2.5 mph or greater);
* Chronic renal insufficiency (Cr \> 2.5 mg/dL)
* Treated diabetes mellitus with FBG \> 180 mg/dL or HbA1C \>9g %
* Hematologic or malignant disorders
* Treated SBP \>160 mmHg and/or DBP \> 95 mmHg ;
* Treated TG \> 250 mg/dL
* Use of systemic vasodilators (e.g., nitrates)
* Morbid Obesity (BMI \> 50 kg/m2)
* Endocrine (thyroid) or metabolic disorders (unless treated and under control)
* Alcohol consumption greater than (2) 4-ounce glasses of table wine, (2) 12-oz bottles of beer or 2 shots of spirits in men or women
* Active IV drug abuse within the past 6 months
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Maryland

OTHER

Sponsor Role collaborator

VA Office of Research and Development

FED

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael Miller, MD

Role: PRINCIPAL_INVESTIGATOR

VA Maryland Health Care System, Baltimore

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

VA Maryland Health Care System, Baltimore

Baltimore, Maryland, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HP-00040456

Identifier Type: OTHER

Identifier Source: secondary_id

CARA-030-08F

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Mediterranean Diet and Mushrooms
NCT04259229 COMPLETED NA
Resistant Potato Starch to Alleviate GWI
NCT05820893 RECRUITING PHASE2